Trustworthy and explainable Artificial Intelligence for Classification of Non-Hodgkin-Lymphoma by Immunophenotype
Michael C. Thrun(Philipps University of Marburg), Alfred Ultsch(Philipps University of Marburg), Cornelia Brendel(Philipps University of Marburg), Andreas Neubauer(RWTH Aachen University), Wolfgang Kern(Munich Leukemia Laboratory (Germany)), Nicole Weit(Beckman Coulter Foundation), Stefan W. Krause(Universitätsklinikum Erlangen), Peter Krawitz(University of Bonn), Jörg Hoffmann(Philipps University of Marburg), Quirin Stier(Ingenieurgesellschaft Auto und Verkehr (Germany))
Cited by 0
Related Papers
Diverse Applications of Nanomedicine
|ACS Nano|2017|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2021|714
Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)
|Journal of Clinical Oncology|2005|573